The global Peptide Cancer Vaccine Market was valued at USD 7.19 billion in 2026 and is projected to reach USD 36.75 billion by 2034, expanding at a CAGR of 22.6% during the forecast period. Market growth is driven by rising demand for targeted cancer therapies, advancements in immunotherapy, and increasing investments in oncology research. Peptide cancer vaccines are emerging as a promising...